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Introduction
A greater understanding of molecular biology has led to 
major breakthroughs in medical treatment for patients 
with renal cell cancer (RCC). Vascular endothelial growth 
factor (VEGF), platelet-derived growth factor, and mam-
malian target of rapamycin (mTOR) signaling pathways 
have become recognized as rational targets for targeted 
therapy [1]. Angiogenesis inhibitors, which include 
sorafenib  (Nexavar®, Bayer), sunitinib  (Sutent®, Pfizer), 
bevacizumab  (Avastin®, Genentech/Roche), pazopanib 
 (Votrient®, Novartis), and axitinib  (Inlyta®, Pfizer) [2–6]; 
and two mTOR inhibitors, temsirolimus  (Torisel®, Pfizer) 
and everolimus  (Afinitor®, Novartis) [7, 8], are all currently 
available as a result of the first breakthrough in metastatic 
RCC therapy, although bevacizumab has not been approved 
in Japan.
We are currently on the verge of the second break-
through. Nivolumab  (Opdivo®, Ono/Bristol-Myers Squibb) 
is a novel targeted agent that has just been launched for 
clinical practice in the treatment of metastatic RCC [9]. 
Nivolumab, which is a fully human immunoglobulin (Ig) 
G4 programmed death 1 (PD-1) antibody, selectively 
inhibits the interaction between PD-1 (which is expressed 
on activated T cells) and PD-1 ligand 1 (PD-L1) and 2 
(PD-L2) (which are expressed on antigen-presenting cells 
[APCs] and cancer cells) [9]. Its promising anti-tumor effi-
cacy and manageable safety profile were demonstrated in 
the phase III Checkmate 025 trial. Nivolumab therapy is 
thus being rapidly introduced in metastatic RCC clinical 
practice in Japan. Recently, excellent treatment results for 
the phase Ia study of atezolizumab (Roche/Genentech), 
which is a humanized anti-PD-L1 monoclonal IgG1 anti-
body, were also demonstrated [10]. The identification of 
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biomarkers to predict the response and side-effects for 
checkpoint inhibitor therapy is urgently needed.
Previously, we reviewed the candidate biomarkers of 
angiogenesis inhibitor therapy in terms of clinical vari-
ables, genetic factors, and circulating proteins and endothe-
lial cells [11]. Regarding biomarkers of RCC patients 
treated with checkpoint inhibitors, however, the role of 
potential predictive biomarkers to benefit the PD-1/PD-L1 
blockade remains controversial and is still under investiga-
tion. Most of the ongoing clinical trials have established 
exploratory biomarker sub-analyses to attempt to identify 
predictive biomarkers of response to PD-1/PD-L1 inhibi-
tion, including PD-L1 expression. Rodriguez-Vida et al. 
reviewed them comprehensively [12]. Research on other 
malignancies may also shed light on biomarker analyses in 
metastatic RCC therapy. Here, we provide a brief overview 
of biomarkers in terms of the tumor immune microenvi-
ronment and clinical factors of RCC and other malignant 
tumor studies.
Tumor immune microenvironment
Cancer cells are recognized by APCs in which cancer cells 
are processed to peptide antigens; cancer cells are then pre-
sented on major histocompatibility class I (MHC-I) or class 
II (MHC-II) molecules as cancer-specific neoantigens [13, 
14]. When CD8-positive cytotoxic T lymphocytes (CTLs) 
recognize these neoantigens presented on the MHC mol-
ecules, the CTLs are activated and proliferate, leading to 
an antigen-specific immune response that kills neoantigen-
bearing cancer cells [13, 14]. However, negative regulators 
exist, namely, the complex of PD-1 and PD-L1/PD-L2. 
PD-L1 and PD-L2, which are known to be expressed on 
the surface of APCs and cancer cells, engage PD-1, which 
expresses on CD8-positive CTLs [13, 14]. When these 
PD-1 and PD-L1/L2 complexes are complete, they trig-
ger an inhibitory signal to the downstream of the T-cell 
receptor (TCR), and block effector and CTL functions [13, 
14]. Here, immune tolerance is achieved. Destruction of 
this immune tolerance using immune checkpoint inhibi-
tors forms the basis for the current novel immune therapy 
(Fig. 1a). In this scenario, the number of neoantigens and 
the expression of MHC molecules (Fig. 1b) and PD-1/
PD-L1 expression (Fig. 1c) can be considered potential 
biomarkers for immune checkpoint inhibitor therapy.
Neoantigens and MHC antigens
Neoantigens, which constitute between 8 and 10 peptides, 
are generally established from tumor-specific mutations, 
presented by MHC class I or MHC class II molecules on 
the surface of APCs, and recognized by CD8-positive 
CTLs that may be able to destroy cancer cells (Fig. 1b) [13, 
14]. Although all of the non-synonymous mutations do not 
always constitute neoantigens, it is probable that the more 
non-synonymous mutations are affected, the more neoan-
tigens develop. Lawrence et al. investigated the heteroge-
neity across patients with 27 cancer types, and revealed 
that the median frequency of non-synonymous mutations 
Fig. 1  Tumor microenvironment and immune checkpoint inhibi-
tors (Fig. 1a). Cancer cells are recognized by APCs in which cancer 
cells are processed to peptide antigen; cancer cells are then presented 
on MHC-I/II as cancer-specific neoantigens. After recognizing these 
neoantigens, the CTLs are activated and proliferate, and kill neo-
antigen-bearing cancer cells (Fig. 1b). When a complex of PD-L1 
expressed by APCs and cancer cells engage PD-1 expressed on CD8-
positive CTLs is complete, immune tolerance is achieved. Destruc-
tion of this immune tolerance using immune checkpoint inhibitors is 
the current novel immune therapy (Fig. 1c). MHC major histocom-
patibility, CTL cytotoxic T lymphocytes, PD-1 programmed death-
1, PD-L1 programmed death-ligand 1, APC antigen-presenting cell, 
TCR T cell receptor
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varied by >1000-fold across cancer types [15]. Melanoma 
and lung cancer showed the highest mutation frequen-
cies, exceeding 100/Mb [15]. These may be attributable 
to extensive exposure to well-known carcinogens, such as 
ultraviolet radiation in the case of melanoma and tobacco 
smoke in the case of lung cancers [15]. Among the can-
cers, RCC (including clear cell cancer and papillary can-
cer) were in the middle position and demonstrated a low 
frequency of mutation burden compared with lung cancer 
and melanoma [15]. Mutation frequencies, however, varied 
markedly across patients within a cancer type. In clear cell 
renal cancer, the frequency ranged from 0.1−10/Mb [15]. 
Rizvi et al. examined the association between the muta-
tion burden and the response of the immune checkpoint 
inhibitor in non-small cell lung cancer (NSCLC) patients 
treated with pembrolizumab  (Keytruda®, MSD), which is a 
humanized antibody for PD-1 [16]. In this study, they used 
whole-exome sequencing and reported that higher non-syn-
onymous mutation burden in tumors was associated with 
improved objective response, durable clinical benefit, and 
longer progression-free survival (PFS) [16]. In addition, 
the efficacy was also correlated with the molecular smok-
ing signature, higher neoantigen burden, and DNA repair 
pathway mutations [16]. Interestingly, although the efficacy 
was significantly correlated with the molecular smoking 
signature, self-reported smoking history did not signifi-
cantly discriminate those most likely to benefit from pem-
brolizumab [16].
A small fraction of advanced colorectal cancer occurs 
as a result of mismatch-repair (MMR) deficiency. Uram 
et al. investigated the efficacy of immune checkpoint 
inhibitors for colorectal and non-colorectal gastrointesti-
nal cancer patients who have MMR deficiency treated with 
pembrolizumab [17]. In this study, whole-exome sequenc-
ing revealed that a mean of 1782 somatic mutations per 
tumor in MMR-deficient tumors was much greater than in 
MMR-proficient tumors, which had a mean of only 73 per 
tumor (p = 0.007) [17]. The median PFS and overall sur-
vival (OS) periods, and objective response rate of patients 
with MMR-deficient colorectal cancer were significantly 
superior to those of patients with MMR-proficient colorec-
tal cancer [HR for PFS and OS, 0.10 (p < 0.001) and 0.22 
(p = 0.05), respectively] [17]. In addition, patients with 
MMR-deficient non-colorectal gastrointestinal cancer had 
responses similar to those of patients with MMR-deficient 
colorectal cancer [17].
Regarding the receiver of the neoantigen, the expres-
sion of MHC antigen might play a role in the efficacy 
of immune checkpoint inhibitors (Fig. 1b). Using two 
independent cohorts of anti-PD-1-treated melanoma 
patients, Johnson et al. reported that MHC-II positivity 
on cancer cells is associated with therapeutic response, 
PFS, and OS, as well as CD4 and CD8 tumor infiltration 
[18]. They concluded that MHC-II expression on cancer 
cells can be identified by melanoma-specific immunohis-
tochemistry using commercially available antibodies for 
HLA-DR in order to improve anti-PD-1 patient selec-
tion [18]. In addition, in an in vivo study using murine 
lung cancer cells and anti-mouse PD-1 antibodies, Wang 
et al. reported that MHC class I and II were significantly 
downregulated in anti-PD1-resistant tumors compared 
with anti-PD1-sensitive tumors [19].
PD‑L1 expression
Before describing PD-L1 expression, we must note that 
there are various factors that influence the PD-L1 expres-
sion and clinical efficacy of immune checkpoint inhibi-
tors (Table 1). There are also various assays, including 
antibodies and cut-off points. There might be a difference 
between newly collected specimens and archival tumor 
samples. Furthermore, PD-L1 expression is dynamic and 
is affected by many factors, including prior therapy and 
the presence of tumor-infiltrating immune cells, which 
lead to intra-tumor differences of PD-L1 expression 
among primary tumors and individual metastatic sites.
Regarding the difference between PD-L1 expression 
and the characteristics of RCC, the Mayo Clinic pub-
lished interesting reports. Thompson et al. reported that 
PD-L1 expression was demonstrated in both clear cell 
RCC tumor cells (present in 66% of specimens) and 
tumor-infiltrating mononuclear cells (present in 59% of 
specimens) by immunohistochemical analysis [20, 21]. 
High levels of PD-L1 within the tumors were signifi-
cantly more likely to exhibit aggressive pathologic fea-
tures, including higher nuclear grade (p < 0.001), positive 
lymph node metastases (p < 0.001), and distant metasta-
ses (p = 0.022) [20, 21]. In addition, they reported that 
both metastatic RCC cells and infiltrating lymphocytes 
express PD-L1 at rates similar to those observed in pri-
mary clear cell RCC tumor lesions [20, 21].
Taube et al. investigated PD-L1 and PD-L2 expres-
sion of cancer cells and infiltrating immune cells in 
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various cancer types. Cell surface PD-L1 expression by 
cancer cells and immune-infiltrating cells varied signifi-
cantly by tumor type, and the most abundant expression 
was demonstrated in melanoma, NSCLC, and RCC [22]. 
Expression of PD-L1 by cancer cells and infiltrating 
immune cells was significantly associated with expres-
sion of PD-1 on lymphocytes [22]. PD-L2 expression was 
also associated with PD-L1 expression [22]. In addition, 
PD-L1 expression on cancer cells demonstrated a signifi-
cant correlation with an objective response to anti-PD-1 
therapy [22]. Daud et al. also investigated the relation-
ship between anti-PD-1 activity and PD-L1 expression in 
patients with advanced melanoma who were treated with 
pembrolizumab in the phase Ib KEYNOTE-001 study 
[23]. In this study of 451 patients with evaluable PD-L1 
expression, 344 (76%) demonstrated PD-L1 expression. 
High PD-L1 expression demonstrated a significant corre-
lation with a high response rate and long PFS (HR 0.76; 
95% confidence interval [CI] 0.71–0.82, p < 0.001) and 
long OS (HR 0.76; 95% CI 0.69–0.83, p < 0.001) [23]. 
Expression of PD-L1 is thus a potential predictive bio-
marker for response and outcome following treatment 
with PD-L1/PD-1 immune checkpoint inhibitor therapy.
From the viewpoint of immune checkpoint inhibitor 
therapy, Hodgkin’s lymphoma is very interesting. In all 
cases of classical Hodgkin’s lymphoma, Hodgkin Reed−
Sternberg cells have copy number alterations of 9p24.1, a 
region that includes PD-L1 and PD-L2, and contributes to 
robust expression of these PD-1 ligands [24]. Amplifica-
tion of 9p24.1 is more common in patients with advanced-
stage Hodgkin’s lymphoma. Like a driver gene mutation, 
amplification of PD-L1 and PD-L2 plays an important 
role in pathogenesis and treatment resistance in this dis-
ease. Before the checkpoint inhibitor therapy era, PD-L1 
and PD-L2 amplification was associated with poor prog-
nosis [24]. Therefore, checkpoint inhibitor therapy was 
warranted. In fact, in the phase I study of nivolumab, 23 
patients with relapsed or refractory Hodgkin’s lymphoma, 
who had already been heavily treated, received nivolumab 
[25]. An excellent objective response rate of 87% was 
obtained, including 17% with a complete response and 70% 
with a partial response [25]. In December 2016 in Japan, 
nivolumab received approval for treatment of patients with 
classical Hodgkin’s lymphoma that had relapsed or pro-
gressed after initial treatment.
Clinical factors
In the cytokine era, prognostic factors that could predict 
outcome in patients with metastatic RCC treated with inter-
feron (IFN)-α as initial systemic therapy were defined by 
the Memorial Sloan Kettering Cancer Center (MSKCC) 
study group [26]. The MSKCC group extracted five vari-
able risk factors for short survival—low Karnofsky per-
formance status (PS), high serum lactate dehydrogenase 
(LDH), low blood hemoglobin (Hb), high corrected serum 
calcium (Ca), and time from initial RCC diagnosis to start 
of IFN-α therapy of <1 year (26). Later, the MSKCC group 
reported the prognostic factors of previously treated RCC 
patients who had received new agents as salvage therapy 
[27]. Three factors, including low Karnofsky PS, low Hb 
level, and high corrected serum Ca level, were extracted as 
the MSKCC prognostic factors for patients treated by the 
second-line therapy [27]. In the molecular targeted therapy 
era, Heng et al. first reported results from a large, multi-
center study of 645 patients with anti-VEGF therapy-naive 
metastatic RCC [28]. In this study, four of the five adverse 
prognostic factors according to MSKCC score (low Hb, 
high corrected Ca level, low PS, and time from diagnosis 
to treatment of <1 year) emerged as independent predictors 
of poor OS [28]. In addition, high levels of neutrophils and 
platelets emerged as independent adverse prognostic fac-
tors [28]. Later, these prognostic factors were applied to 
patients previously treated with targeted therapy, in addi-
tion to previously validated populations in first-line tar-
geted therapy [29]. These six risk factors are now widely 
used and are known as the International Metastatic RCC 
Database Consortium (IMDC) criteria. In the immune 
checkpoint inhibitor era, these known and widely used cri-
teria must be re-evaluated.
Baseline clinical factors associated with OS after 
immune checkpoint blockade for melanoma patients 
treated by pembrolizumab have been reported [30]. Rela-
tive eosinophil count ≥1.5%, relative lymphocyte count 
≥17.5%, ≤2.5-fold elevation of LDH, and absence of 
metastasis other than soft tissue/lung were extracted as 
independent favorable prognostic factors (all p < 0.001). In 
terms of eosinophil count, however, another group reported 
that eosinophilia was a favorable prognostic factor inde-
pendent of therapeutic agents [31].
Other groups also reported serum LDH level as a prog-
nostic factor for advanced/metastatic melanoma patients 
treated with nivolumab or pembrolizumab [32]. After a 
median follow-up of 9 months, patients with an elevated 
baseline LDH had a significantly shorter OS compared to 
patients with normal LDH (6 month OS 60.8 vs 81.6% and 
12 month OS 44.2 vs 71.5% (p = 0.0292) [32]. In addi-
tion, patients with a relative increase of >10% from ele-
vated baseline LDH had a significantly shorter OS com-
pared to patients with a decrease or <10% increase (4.3 vs 
15.7 months, p = 0.00623) [32]. They concluded that LDH 
could be a useful marker at baseline as well as during treat-
ment to predict early response or progression in patients 
with advanced melanoma who received immune checkpoint 
inhibitor therapy [32]. Similarly, Nakayama et al. reported 
Int J Clin Oncol 
1 3
pretreatment as well as on-treatment prognostic factors for 
patients with melanoma treated with nivolumab [33]. The 
Eastern Cooperative Oncology Group (ECOG) PS ≥1, 
maximum tumor diameter of ≥30 mm, elevated LDH, 
and elevated C-reactive protein (CRP) were significantly 
associated with poor OS [HR 0.29 (p < 0.001), HR 0.40 
(p = 0.003), HR 0.29 (p < 0.001), HR 0.42 (p = 0.004), 
respectively] on univariate analysis [33]. Among these fac-
tors, PS and LDH were identified as independent variables 
by multivariate analysis [33]. In addition, for early treat-
ment responding markers, patients with absolute lympho-
cyte count ≥1000/μl [week 3, HR 0.40 (p = 0.004); week 
6, HR 0.33 (p = 0.001)] and absolute neutrophil count 
<4000/μl [week 3, HR 0.46 (p = 0.014); week 6, HR 0.51 
(p = 0.046)] had significantly better OS [33].
The final topic in terms of clinical factors is adverse 
events. Are adverse events associated with the efficacy 
of immune checkpoint inhibitors? In melanoma patients 
treated with nivolumab, immune-related adverse events 
(irAEs) are reported to be associated with improved sur-
vival [34]. In this study, irAEs of any grade were observed 
in 68.2% of patients (101 of 148). A statistically significant 
OS difference was noted among patients with any grade of 
irAE versus those without (p < 0.001), and OS benefit was 
noted in patients who reported ≥3 irAE events (p < 0.001) 
[34]. In addition, rash and vitiligo correlated with statisti-
cally significant OS differences in patients with metastatic 
disease (p = 0.004 and p = 0.028, respectively) [34].
Conclusion
In this review, we introduced the current candidate bio-
markers of immune checkpoint inhibitor therapy. Based 
on the mechanism of efficacy, the number of neoantigens 
and expression of MHC molecules are strong candidate 
biomarkers (Fig. 1b). Despite the various interference fac-
tors (Table 1), PD-1/PD-L1 expression can be considered a 
potential biomarker (Fig. 1c). Regarding clinical factors in 
metastatic RCC patients, we already have two well-known 
criteria, including MSKCC and IMDC; however, these 
widely used criteria must be re-evaluated. Finally, we intro-
duced serum clinical factors and severity of adverse effects 
as candidate biomarkers of favorable efficacy (Fig. 2). 
Although further implementation in prospective studies is 
necessary, if validated, these biomarkers can be utilized to 
measure therapeutic response and design treatment strate-
gies for metastatic RCC.
Acknowledgements This work was partly supported by the Smoking 
Research Foundation and Grants-in-Aid for Scientific Research from 
the Ministry of Education, Culture, Sports, Science and Technology, 
Japan.
Compliance with ethical standards 
Conflict of interest TY received remuneration for a lecture from 
Astellas (Tokyo, Japan), Sanofi Japan (Tokyo, Japan), Pfizer Japan 
(Tokyo, Japan), Novartis Pharma Japan (Tokyo, Japan), Ono Pharma 
(Osaka, Japan), and Daiichi-Sankyo (Tokyo, Japan). The other authors 
have declared no conflict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Linehan WM, Vasselli J, Srinivasan R et al (2004) Genetic 
basis of cancer of the kidney: disease-specific approaches to 
therapy. Clin Cancer Res 10:6282S–6289S
 2. Escudier B, Eisen T, Stadler WM, TARGET Study Group et al 
(2007) Sorafenib in advanced clear-cell renal-cell carcinoma. 
N Engl J Med 356:125–134
 3. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib ver-
sus interferon alfa in metastatic renal cell carcinoma. N Engl J 
Med 356:115–124
 4. Escudier B, Pluzanska A, Koralewski P, AVOREN Trial inves-
tigators et al (2007) Bevacizumab plus interferon alfa-2a for 
treatment of metastatic renal cell carcinoma: a randomised, 
double-blind phase III trial. Lancet 370:2103–2111
 5. Rini BI, Escudier B, Tomczak P et al (2011) Comparative 
effectiveness of axitinib versus sorafenib in advanced renal 
cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 
378:1931–1939
 6. Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib ver-
sus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 
369:722–731
 7. Hudes G, Carducci M, Tomczak P, Trial Global ARCC et al 
(2007) Temsirolimus, interferon alfa, or both for advanced 
renal-cell carcinoma. N Engl J Med 356:2271–2281
 8. Motzer RJ, Escudier B, Oudard S, RECORD-1 Study Group 
et al (2008) Efficacy of everolimus in advanced renal cell 
Fig. 2  Clinical factors as candidate biomarkers. In addition to vari-
ous baseline factors, correlations between immune checkpoint inhibi-
tor efficacy and adverse effects have been reported. PS performance 
status, HB hemoglobin, LDH lactate dehydrogenase, Ca calcium, Dx 
diagnosis, LLN lower limit of normal range, ULN upper limit of nor-
mal range, CRP C-reactive protein
 Int J Clin Oncol
1 3
carcinoma: a double-blind, randomised, placebo-controlled 
phase III trial. Lancet 372:449–456
 9. Motzer RJ, Escudier B, McDermott DF, CheckMate 025 Inves-
tigators et al (2015) Nivolumab versus everolimus in advanced 
renal-cell carcinoma. N Engl J Med 373:1803–1813
 10. McDermott DF, Sosman JA, Sznol M et al (2016) Atezoli-
zumab, an anti-programmed death-ligand 1 antibody, in meta-
static renal cell carcinoma: long-term safety, clinical activity, 
and immune correlates from a phase Ia study. J Clin Oncol 
34:833–842
 11. Yuasa T, Takahashi S, Hatake K et al (2011) Biomarkers to pre-
dict response to sunitinib therapy and prognosis in metastatic 
renal cell cancer. Cancer Sci 102:1949–1957
 12. Rodriguez-Vida A, Strijbos M, Hutson T (2016) Predictive and 
prognostic biomarkers of targeted agents and modern immuno-
therapy in renal cell carcinoma. ESMO Open 1:e000013
 13. Dudley JC, Lin MT, Le DT et al (2016) Microsatellite instability 
as a biomarker for PD-1 blockade. Clin Cancer Res 22:813–820
 14. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer 
immunotherapy. Science 348:69–74
 15. Lawrence MS, Stojanov P, Polak P et al (2013) Mutational het-
erogeneity in cancer and the search for new cancer-associated 
genes. Nature 499:214–218
 16. Rizvi NA, Hellmann MD, Snyder A, Cancer Immunology et al 
(2015) Mutational landscape determines sensitivity to PD-1 
blockade in non-small cell lung cancer. Science 348:124–128
 17. Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors 
with mismatch-repair deficiency. N Engl J Med 372:2509–2520
 18. Johnson DB, Estrada MV, Salgado R et al (2016) Melanoma-
specific MHC-II expression represents a tumour-autonomous 
phenotype and predicts response to anti-PD-1/PD-L1 therapy. 
Nat Commun 7:10582
 19. Wang X, Schoenhals JE, Li A et al (2016) Suppression of type 
I IFN signaling in tumors mediates resistance to anti-PD-1 
treatment that can be overcome by radiotherapy. Cancer Res 
77:839–850
 20. Thompson RH, Gillett MD, Cheville JC et al (2004) Costimula-
tory B7-H1 in renal cell carcinoma patients: indicator of tumor 
aggressiveness and potential therapeutic target. Proc Natl Acad 
Sci USA 101:17174–17179
 21. Thompson RH, Dong H, Kwon ED (2007) Implications of 
B7-H1 expression in clear cell carcinoma of the kidney for prog-
nostication and therapy. Clin Cancer Res 13:709s–715s
 22. Taube JM, Klein A, Brahmer JR et al (2014) Association of 
PD-1, PD-1 ligands, and other features of the tumor immune 
microenvironment with response to anti-PD-1 therapy. Clin Can-
cer Res 20:5064–5074
 23. Daud AI, Wolchok JD, Robert C et al (2016) Programmed 
death-ligand 1 expression and response to the anti-programmed 
death 1 antibody pembrolizumab in melanoma. J Clin Oncol 
34:4102–4109
 24. Roemer MG, Advani RH, Ligon AH et al (2016) PD-L1 and 
PD-L2 genetic alterations define classical Hodgkin lymphoma 
and predict outcome. J Clin Oncol 34:2690–2697
 25. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade 
with nivolumab in relapsed or refractory Hodgkin’s lymphoma. 
N Engl J Med 372:311–319
 26. Motzer RJ, Murphy BA, Bacik J et al (2001) Interferon-alfa as a 
comparative treatment for clinical trials of new therapies against 
advanced renal cell carcinoma. J Clin Oncol 20:289–296
 27. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors 
for survival in previously treated patients with metastatic renal 
cell carcinoma. J Clin Oncol 22:454–463
 28. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors 
for overall survival in patients with metastatic renal cell carci-
noma treated with vascular endothelial growth factor-targeted 
agents: results from a large, multicenter study. J Clin Oncol 
27:5794–5799
 29. Ko JJ, Xie W, Kroeger N et al (2015) The International Meta-
static Renal Cell Carcinoma Database Consortium model as a 
prognostic tool in patients with metastatic renal cell carcinoma 
previously treated with first-line targeted therapy: a population-
based study. Lancet Oncol 16:293–300
 30. Weide B, Martens A, Hassel JC et al (2016) Baseline biomarkers 
for outcome of melanoma patients treated with pembrolizumab. 
Clin Cancer Res 22:5487–5496
 31. Moreira A, Leisgang W, Schuler G et al (2017) Eosinophilic 
count as a biomarker for prognosis of melanoma patients and its 
importance in the response to immunotherapy. Immunotherapy 
9:115–121
 32. Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehy-
drogenase as an early marker for outcome in patients treated 
with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 
114:256–261
 33. Nakamura Y, Kitano S, Takahashi A et al (2016) Nivolumab for 
advanced melanoma: pretreatment prognostic factors and early 
outcome markers during therapy. Oncotarget 7:77404–77415
 34. Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab 
in resected and unresectable metastatic melanoma: characteris-
tics of immune-related adverse events and association with out-
comes. Clin Cancer Res 22:886–894
